Could a cheaper shingles booster offer same protection?
NCT ID NCT07753265
First seen Aug 07, 2026 · Last updated Aug 07, 2026
Summary
This trial tests whether a single dose of a live-attenuated shingles vaccine can effectively boost immunity in adults aged 50 and older who have already received the recombinant shingles vaccine. The study measures antibody and cellular immune responses after the booster. If it works, it might provide a more affordable or convenient option for maintaining shingles protection.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- live-attenuated zoster vaccine
- What this could lead to
- If successful, this could offer a more accessible or cost-effective booster option for shingles prevention in older adults.
- What could go wrong
- This is an early-phase trial with only 100 participants, so results may not be conclusive. The live vaccine carries a small risk of causing shingles-like symptoms, especially in those with weakened immunity.
Why investors are watching
Changchun BCHT Biotechnology is testing whether its live-attenuated shingles vaccine can work as a booster after people have already received a recombinant shingles vaccine. For a small company, this early-phase study of 100 participants could show whether its vaccine has a role in a crowded prevention market, which would matter for its future product value.
If it works: A positive result could show that BCHT's vaccine offers a useful booster option, potentially expanding its use and strengthening the company's position in shingles prevention. This could lead to more clinical development and commercial interest.
If it fails: Early-phase trials often fail to show the hoped-for immune response, and a weak result could limit the vaccine's prospects and hurt the company's credibility. Delays in enrollment or analysis could also slow progress and increase costs.
AI-written from the trial record. Speculative, and not investment advice.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Early phase 1
The earliest testing in people: a first look at safety, in a very small group.
- Participants
-
About 100 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Aug 2026
An estimate. Start dates often move.
- Expected to finish
-
Sep 2026
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
50 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Age ≥ 50 years old; * The participant can provide personal informed consent and sign the informed consent form; * temperature ≤ 37.0℃ on the day of administration; * capable of complying with the requirements of the clinical trial protocol to complete the trial. Exclusion Criteria: * Subjects with immunodeficiency or immunosuppression caused by underlying diseases or treatments, including primary/acquired immunodeficiency (e.g., AIDS and other virus-induced immunodeficiency), hematologic malignancies (leukemia, lymphoma or other bone marrow/lymphoid neoplasms), ongoing immunosuppressive therapy, or radiotherapy/chemotherapy for malignancies. * Subjects with a history of allergic reaction to any component of the investigational product. * Subjects with acute infection or acute exacerbation of chronic infection (vaccination should be deferred). * Women of non-postmenopausal status with positive pregnancy test, pregnant or lactating women, or those planning pregnancy within 6 months. * Subjects with prior history of herpes zoster. * Subjects with prior receipt of varicella or herpes zoster vaccine. * Receipt of live-attenuated vaccines within 14 days, or subunit/inactivated vaccines within 7 days prior to study vaccination. * Receipt of whole-blood, plasma or immunoglobulin within 5 months before, or within 3 weeks after study vaccination. * Receipt of investigational drugs from other clinical trials within 1 month before study vaccination, current participation in another clinical trial, or planned use of investigational agents during study period. * Current or planned use of salicylates (including aspirin, diflunisal, etc.). * Uncontrolled abnormal blood pressure at screening (systolic blood pressure ≥160 mmHg and/or diastolic blood pressure ≥100 mmHg despite medication). Subjects meeting contraindications or precautions specified in the product's prescribing information. * Any condition that, in the Investigator's opinion, may interfere with study evaluations.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Herpse zoster are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.